Hepatoblastoma is the most frequent liver cancer affecting infants and children. While cure is possible in approximately 80% of patients, many children progress on initial therapy with refractory disease, having not achieved remission (refractory), or relapse after having achieved remission (relapse). No standards of care exist for such children, as relapsed/refractory hepatoblastoma (rrHBL) has not been formally studied to any significant extent through the international and national cooperative group mechanisms. This registry will fill this gap.

The Relapsed/Refractory Hepatoblastoma (rrHBL) Registry provides the infrastructure for acquisition of clinical data, biological specimens, and imaging enabling necessary advancements in knowledge, treatment standards and effectiveness, and biology studies, ultimately leading to the development of novel therapies. The Registry is a key core initiative of the Liver Tumor Research Consortium (LTRC), which is a collaboration among physicians and other care providers, researchers and scientists, and additional stakeholders (patients, parents), dedicated to stimulating research initiatives to better understand disease biology and pathophysiology and innovate novel therapies.